source
- EU regulators endorse Eli Lilly’s oral GLP-1 pill orforglipronThe European Medicines Agency’s human medicines committee (CHMP) has given a positive opinion on Eli Lilly’s oral GLP-1 medication, orforglipron, providing the drug with EU regulatory backing. The…
- City Therapeutics raises $200 million in IPO to fund next-gen RNAi programsCity Therapeutics, a biotech focused on RNA interference, completed a $200 million initial public offering, selling about 11.1 million shares at $18 each. The proceeds will back three drug candida…